ResMed Inc (ASX: RMD) Share Price and News

Dr Farrell before founding ResMed served as vice president of research and development at various subsidiaries of Baxter International, Inc. (NYSE: BAX), from July 1984 to June 1989, and managing director of the Baxter Center for Medical Research Pty Ltd., a Baxter subsidiary, from August 1985 to June 1989. He served on the Visiting Committee of the Harvard/MIT Health Sciences & Technology Program from 1998 through 2018 and currently serves on the MIT Dean of Engineering's Advisory Council.

Mr Taylor in 1987 founded Pyxis Corporation, a manufacturer of automated drug dispensers for hospitals, where he served as chairman, president, and CEO until its purchase by Cardinal Health, Inc., in 1996. For six years before founding Pyxis, Mr. Taylor was responsible for operations and international sales at Hybritech, Inc., a biotechnology company. Before joining Hybritech, he served for 10 years in management roles at Allergan plc (NYSE: AGN), a pharmaceutical company. From 1998-2001, he was a general partner at Enterprise Partners Venture Capital. He is a member of the compliance oversight and governance committees.

Mr Farrell serves on the board of directors of Zimmer Biomet (NYSE: ZBH), a public company that provides implantable musculoskeletal medical devices for patients globally. He is also a member of two committees at Zimmer Biomet: the compensation and management development committee, as well as the quality, regulatory & technology committee, where he also serves as Chair. Mick also volunteers for non-profit organizations: Boston College Engineering Advisory Board, UC San Diego Rady School of Management Dean's Advisory Council, Rady Children's Hospital Board, and as a trustee for Father Joe's Villages project for the homeless in San Diego, California. Before joining Resmed, Mick worked in management consulting, biotechnology, chemicals and metals manufacturing at companies including Arthur D. Little, Sanofi Genzyme, Dow Chemical, and BHP.

Ms Burt, principal of Burt-Hilliard Investments since 2008, is a private investor with more than 35 years of experience in corporate governance, operations, strategy, finance, mergers and acquisitions, and investment banking. Since 2013, Ms. Burt has served as a senior advisor and a member of the operating council of Consonance Capital Partners, a New York-based private equity firm focused on investments in the healthcare industry. Ms. Burt serves on the boards of IQVIA Holdings Inc. (NYSE: IQV), a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, where she chairs the leadership development and compensation committee and is a member of the audit committee; and serves on the board of one private company, WellDyne. She is a member of the governance and compliance, privacy and quality committee.

Ms Drexler is an entrepreneur with expertise in the fields of digital health, medical devices, and diagnostics. Currently, she serves on the boards of Outset Medical (NASDAQ: OM), a medtech company innovating dialysis treatment, where she chairs the nomination and governance committee and is a member of the compensation committee. Ms. Drexler is also on the board of two private companies: VIDA Diagnostics and Huma.ai. She is chair of the compensation committee, and a member of the governance committee.

Mr De Witte is a public company chief executive officer and board director with experience leading international growth for global technology and medtech companies. He is a member of its audit and compliance oversight committees. He has served in a variety of operational and business leadership roles over the past 30 years. Most recently, he served as president, chief executive officer, and a member of the board of directors of Integra LifeSciences, regenerative tissue technologies and neurosurgical solutions. He is a member of the compliance oversight committee.

Ms Gill is chief executive officer of the Asia Pacific Medical Technology Association (APACMed), the only regional association to provide a unified voice for the medical device and in-vitro diagnostics industry in Asia Pacific. She also holds several board positions: since 2019 she has been a member of the Innovation Board of Directors at MAS Holdings, an apparel manufacturer in Southeast Asia with 53 manufacturing facilities in 17 countries. Since January 2022, she has been a board member at Amway, a global leader in home, health, and beauty products, and serves as a member of the audit committee. Since January 2024 she is also a member of the academic committee of the China-Asean science and technology cooperation center for public health at Peking University, China. She is a member of its compensation and leadership development and leads the compliance, privacy and quality committee.

Dr Hernandez is head of clinical research, health economics, and outcomes research at Google (NASDAQ: GOOGL). He joined Alphabet in 2016 where he built and led teams at Verily and Google leveraging artificial intelligence to assist in promoting healthy lifestyles, diagnosing cancer, preventing blindness, and more. Dr. Hernandez is a medical device and digital health executive with over 30 years of experience in clinical research, health economics, market access, and global commercial strategy. Prior to joining Alphabet, he was vice president of global health economics and outcomes research at Abbott Laboratories (NYSE: ABT), and vice president of health economics and clinical research at Boston Scientific Corporation (NYSE: BSX). He is a member of the compliance oversight committee.

Mr Tan is corporate vice president and managing director of the core Microsoft (NASDAQ: MSFT) Research Lab in Redmond, Washington. He is also an affiliate professor of computer science and engineering at the University of Washington Seattle since 2007, where he co-founded the National Science Foundation Center for Sensorimotor Neural Engineering and chaired its industry advisory board. Dr. Tan is an executive who has built and run multidisciplinary global innovation teams - leveraging expertise in hardware and devices, software development, applied machine learning and artificial intelligence, human-computer interaction, and applied science to make an impact in areas such as autonomous navigation, entertainment and consumer products, as well as health and life sciences. He is a member of the compensation and leadership development committee.

Mr DelOrefice currently serves as executive vice president and chief financial officer (CFO) of Becton, Dickinson and Company (NYSE: BDX), including responsibility for the Information Technology and Global Services and the Strategy and Corporate Development organizations. He brings over 30 years of audit, accounting, finance, operational, and strategic expertise. Before joining BD in September 2021, Mr. DelOrefice served in many roles at Johnson & Johnson (NYSE: JNJ) including most recently as vice president of investor relations and previously as CFO of J&J's consumer and medical device business segments for North America, along with roles in finance leadership for supply chain, corporate mergers and acquisitions, consumer research and development, and business development for J&J's North America pharmaceutical business. Before J&J, Mr. DelOrefice held positions of increasing responsibility in accounting, financial reporting, global audit, and supply chain finance at AstraZeneca (LON: AZN), AET Films, and Ametek (NYSE: AME).

--

-